Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease (original) (raw)
Collins, P.L. et al. Fields Virology. (eds. Knipe, D.M. & Howley, P.M.) 1443–1486 (Raven Press, New York, 2001). Google Scholar
Glezen, W.P., Taber, L.H., Frank, A.L. & Kasel, J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child.140, 543–546 (1986). CASPubMed Google Scholar
Shay, D.K. et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. J. Am. Med. Assoc.282, 1440–1446 (1999). ArticleCAS Google Scholar
Kim, H.W. et al. Respiratory Ssyncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89, 422–434 (1969). ArticleCAS Google Scholar
Polack, F.P. et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med.196, 859–865 (2002). ArticleCAS Google Scholar
Graham, B.S. et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol.151, 2032–2040 (1993). CASPubMed Google Scholar
Moghaddam, A. et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med.12, 905–907 (2006). ArticleCAS Google Scholar
Srikiatkhachorn, A. & Braciale, T.J. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med.186, 421–432 (1997). ArticleCAS Google Scholar
Connors, M. et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol.66, 7444–7451 (1992). CASPubMedPubMed Central Google Scholar
Connors, M. et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol.68, 5321–5325 (1994). CASPubMedPubMed Central Google Scholar
Connors, M. et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine10, 475–484 (1992). ArticleCAS Google Scholar
Murphy, B.R., Sotnikov, A.V., Lawrence, L.A., Banks, S.M. & Prince, G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine8, 497–502 (1990). ArticleCAS Google Scholar
Murphy, B.R. & Walsh, E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol.26, 1595–1597 (1988). CASPubMedPubMed Central Google Scholar
Prince, G.A. et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol.57, 721–728 (1986). CASPubMedPubMed Central Google Scholar
Wu, H. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol.368, 652–665 (2007). ArticleCAS Google Scholar
Johnson, S. et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J. Infect. Dis.180, 35–40 (1999). ArticleCAS Google Scholar
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics112, 1442–1446 (2003).
Graham, B.S. et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest.88, 1026–1033 (1991). ArticleCAS Google Scholar
Murphy, B.R. et al. Immunization of cotton rats with the fusion (F) and large G) glycoproteins of respiratory syncytial virus ( (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine7, 533–540 (1989). ArticleCAS Google Scholar
Mapletoft, J.W. et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J. Gen. Virol.89, 250–260 (2008). ArticleCAS Google Scholar
Polack, F.P., Hoffman, S.J., Crujeiras, G. & Griffin, D.E. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med.9, 1209–1213 (2003). ArticleCAS Google Scholar
Bachmann, M.F. et al. The role of antibody concentration and avidity in antiviral protection. Science276, 2024–2027 (1997). ArticleCAS Google Scholar
Fleury, D. et al. A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site. Nat. Struct. Biol.6, 530–534 (1999). ArticleCAS Google Scholar
Arbiza, J. et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol.73, 2225–2234 (1992). ArticleCAS Google Scholar
Melendi, G.A. et al. C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J. Virol.81, 991–999 (2007). ArticleCAS Google Scholar
Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol.1, 135–145 (2001). ArticleCAS Google Scholar
Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature438, 364–368 (2005). ArticleCAS Google Scholar
Rudd, B.D. et al. Type I interferon regulates respiratory virus infected dendritic cell maturation and cytokine production. Viral Immunol.20, 531–540 (2007). ArticleCAS Google Scholar
Rudd, B.D. et al. MyD88-mediated instructive signals in dendritic cells regulate pulmonary immune responses during respiratory virus infection. J. Immunol.178, 5820–5827 (2007). ArticleCAS Google Scholar
Smit, J.J. et al. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE3, e1720 (2008). Article Google Scholar
Polack, F.P. et al. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl. Acad. Sci. USA102, 8996–9001 (2005). ArticleCAS Google Scholar
Kawai, T., Adachi, O., Ogawa, T., Takeda, K. & Akira, S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity11, 115–122 (1999). ArticleCAS Google Scholar
Kurt-Jones, E.A. et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol.1, 398–401 (2000). ArticleCAS Google Scholar
Rudd, B.D. et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J. Immunol.176, 1937–1942 (2006). ArticleCAS Google Scholar
Lindemans, C.A. et al. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-κB–dependent mechanism. J. Immunol.176, 5529–5537 (2006). ArticleCAS Google Scholar
Gavin, A.L. et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science314, 1936–1938 (2006). ArticleCAS Google Scholar
Kool, M. et al. Cutting Edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol.181, 3755–3759 (2008). ArticleCAS Google Scholar
Polack, F.P. et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med.5, 629–634 (1999). ArticleCAS Google Scholar
Brokstad, K.A. et al. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine13, 1522–1528 (1995). ArticleCAS Google Scholar
Knossow, M. et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology302, 294–298 (2002). ArticleCAS Google Scholar
Barbey-Martin, C. et al. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology294, 70–74 (2002). ArticleCAS Google Scholar
Sauter, N.K. et al. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry28, 8388–8396 (1989). ArticleCAS Google Scholar
Kolokoltsov, A.A. et al. Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus. J. Virol.81, 7786–7800 (2007). ArticleCAS Google Scholar
Liu, P. et al. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus–infected airway epithelial cells. J. Virol.81, 1401–1411 (2007). ArticleCAS Google Scholar
Bhoj, V.G. et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA105, 14046–14051 (2008). ArticleCAS Google Scholar
Hussell, T., Baldwin, C.J., O'Garra, A. & Openshaw, P.J. CD8+ T cells control TH2-driven pathology during pulmonary respiratory syncytial virus infection. Eur. J. Immunol.27, 3341–3349 (1997). ArticleCAS Google Scholar
Neuzil, K.M. et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine15, 525–532 (1997). ArticleCAS Google Scholar
García-Barreno, B. et al. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J. Virol.63, 925–932 (1989). PubMedPubMed Central Google Scholar